Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Global Partners LP Common Units (GLP) Q4 2025 Earnings Call Transcript
12:17pm, Friday, 27'th Feb 2026
Global Partners LP Common Units (GLP) Q4 2025 Earnings Call Transcript
Global Partners Reports Fourth-Quarter and Full-Year 2025 Financial Results
08:00am, Friday, 27'th Feb 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today reported financial results for the fourth quarter and full year ended December 31
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
01:35pm, Thursday, 26'th Feb 2026
Analysis of 1,200+ patent documents reveal which programs are building durable exclusivity, and which may not be Analysis of 1,200+ patent documents reveal which programs are building durable exclusiv
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
07:00am, Thursday, 26'th Feb 2026
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anti
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3 In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%)
Hims & Hers Health: The GLP-1 Party Is Over
11:07am, Wednesday, 25'th Feb 2026
Hims & Hers Health, Inc. is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. HIMS' reliance on compounded GLP-1 drugs has faltered, with regulatory
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?
09:41am, Wednesday, 25'th Feb 2026
LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?
12:30am, Wednesday, 25'th Feb 2026
Turning $100,000 into $1 million is a task few stocks can accomplish. Novo Nordisk doesn't seem likely to do so, especially given the challenges it is facing.
Savings Programs that offer Affordable Access to GLP-1s Available at Kroger
11:40am, Tuesday, 24'th Feb 2026
Paired with nutrition support, fresh food and easy access to dietitians, Kroger can help customers reach wellness goals CINCINNATI, Feb. 24, 2026 /PRNewswire/ -- The Kroger Co. family of companies an
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
08:54am, Tuesday, 24'th Feb 2026
Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027. The move aims to make the treatments more ac
Hims & Hers Health After The GLP-1 Collapse
08:47am, Tuesday, 24'th Feb 2026
Hims & Hers Health's revenue grew 59% to $2.35B in 2025, while adjusted EBITDA surged nearly 80% to $318M. Operating cash flow reached $300M, with $929M in liquidity, reinforcing balance sheet strengt
First Wave of Influencers with Combined Reach of Over 23 Million to Drive National Awareness Lake Oswego, Oregon--(Newsfile Corp. - February 24, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a leadin
Hims & Hers Q4 Earnings Show Growth Amid GLP-1 Scrutiny
06:30am, Tuesday, 24'th Feb 2026
Hims & Hers Health delivered strong FY25 results with 59% revenue growth to $2.35B and 13% subscriber growth, but faces near-term margin pressure. Management guided FY26 revenue of $2.7–$2.9B and Ad
Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push
09:41am, Monday, 23'rd Feb 2026
Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart: a new injector pen, a new box, another reminder to refill, and one more item for the sharps bin. Eli Lilly is trying to
SureNano Science Ltd. Acquires GlucaPharm Inc., Advancing Second-Generation FDA Pathway GLP-1 Drug Development
09:00am, Monday, 23'rd Feb 2026
GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to Ozempic®, Wegovy®, Mounjaro®, but with reduced risk of adverse events) discovered by researchers at Syracuse Univer
